CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
eribulin mesylatedrug
Likely dose
eribulin mesylate 1.4 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00337129
NCT00337129Phase 2Completed
CompareCT.gov

Phase II Evaluation of E7389 (NSC-707389) in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

National Cancer Institute (NCI)·interventional·Posted Jun 15, 2006·Updated Aug 25, 2015

In Brief

A Phase 2 clinical trial evaluating eribulin mesylate for Head and Neck Cancer. Completed, enrolled 42 participants across 139 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well E7389 works in treating patients with metastatic or recurrent head and neck cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 15, 2006
Enrollment StartMay 1, 2006
Primary CompletionAug 1, 2008
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.0 years ago

Interventions

eribulin mesylatedrug

1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.